Landscapes / Companies
Alfasigma S.p.A. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
1
in active trials · 3 in all
Trials
4 active
13 since 2021
Drugs1
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
JAK inhibitor |
Approved in the EU | Jun 2027Phase 3 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | Jun 2027 · Phase 3 trial completes | ||||
| Also tested for | Axial Spondyloarthritis, Ulcerative Colitis and 2 more | ||||
| Open drug page | |||||
About
- No active trial
- Rifaximin delayed release, Velusetrag
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021